Giant prolactinomas in adolescence: an uncommon cause of blindness

By Semple Patrick   Fieggen Graham   Parkes Jeannette   Levitt Naomi  

Child's Nervous System, Vol. 23, Iss. 2, 2007-02 ,pp. : 213-217

Springer Publishing Company

Access to resources Recommend Favorite

Bromocriptine and the expression of c-myc and c-fos in human prolactinomas

By Burdman Jose A.   Guerra Liliana N.   Calabrese Maria T.   Basso Armando  

Neurological Research, Vol. 23, Iss. 7, 2001-10 ,pp. : 721-723

Maney Publishing

Access to resources Recommend Favorite

Synergistic inhibition of lipid peroxidation by vitamin E and a dopamine agonist, cabergoline

By Sohmiya Makoto   Tanaka Makoto   Okamoto Koichi   Fujisawa Akio   Yamamoto Yorihiro  

Neurological Research, Vol. 26, Iss. 4, 2004-06 ,pp. : 418-421

Maney Publishing

Access to resources Recommend Favorite

Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas

By Mukdsi Jorge   Paul Ana   Petiti Juan   Gutiérrez Silvina   Aoki Agustín   Torres Alicia  

Acta Neuropathologica, Vol. 112, Iss. 4, 2006-10 ,pp. : 491-501

Springer Publishing Company

Access to resources Recommend Favorite

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson’s disease – a subjective view

By Horowski R.  

Journal of Neural Transmission, Vol. 114, Iss. 1, 2007-01 ,pp. : 127-134

Springer Publishing Company

Access to resources Recommend Favorite